Carna Biosciences,Inc. (4572.T) Financial Statements

Income statement

Metric	TTM	2025	2024	2023	2022
Revenue
Total Revenue	619.0M	579.0M	636.0M	1.6B	1.4B
Cost of Revenue	52.4M	190.9M	170.5M	175.3M	171.6M
Gross Profit	131.3M	388.1M	465.7M	1.5B	1.2B
Operating Expenses
R&D Expense	—	—	—	—	—
SG&A Expense	589.7M	2.5B	2.5B	2.6B	2.5B
General & Admin Expense	—	—	—	—	—
Selling & Marketing Expense	—	—	—	—	—
Other Expenses	—	—	—	—	—
Total Operating Expenses	589.7M	2.5B	2.5B	2.6B	2.5B
Cost and Expenses	2.7B	2.7B	2.7B	2.7B	2.7B
Operating Income (EBIT)	(2.0B)	(2.1B)	(2.1B)	(1.1B)	(1.3B)
Non-Operating
Interest Income	814.0K	3.9M	14.5M	170.0K	147.0K
Interest Expense	13.2M	9.8M	3.0M	3.5M	5.3M
Net Interest Income	(12.4M)	(5.9M)	11.5M	(3.3M)	(5.2M)
Other Non-Op Income/Expense	(30.5M)	(69.9M)	(4.6M)	(9.3M)	(8.9M)
Non-Operating Income (excl Interest)	725.0K	2.1M	29.6M	586.0K	5.4M
EBT (Pre-Tax Income)	(512.1M)	(2.2B)	(2.2B)	(1.1B)	(1.3B)
Income Tax Expense	1.1M	1.9M	4.6M	22.0M	26.1M
Bottom Line
Net Income	(2.2B)	(2.2B)	(2.2B)	(1.2B)	(1.3B)
Earnings from Cont. Ops	—	—	—	—	—
Earnings from Discont. Ops	—	—	—	—	—
Bottom Line Net Income	(2.2B)	(2.2B)	(2.2B)	(1.2B)	(1.3B)
Per Share
Basic EPS	(¥114)	(¥114)	(¥122)	(¥69)	(¥99)
Diluted EPS	(¥114)	—	—	—	—
Revenue Per Share	¥32	¥30	¥36	¥97	¥102
Shares
Basic Shares Outstanding	19.2M	19.1M	17.9M	16.8M	13.6M
Diluted Shares Outstanding	—	—	—	—	—
Profitability Metrics
EBITDA	—	—	(2.0B)	(1.1B)	(1.2B)
D&A	—	—	31.2M	35.6M	33.8M
EBIT	(2.0B)	(2.1B)	(2.1B)	(1.1B)	(1.3B)

As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Mar 1, 2026